216 related articles for article (PubMed ID: 15501978)
1. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.
Miederer M; McDevitt MR; Borchardt P; Bergman I; Kramer K; Cheung NK; Scheinberg DA
Clin Cancer Res; 2004 Oct; 10(20):6985-92. PubMed ID: 15501978
[TBL] [Abstract][Full Text] [Related]
2. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
[TBL] [Abstract][Full Text] [Related]
4. Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma.
Cheung NK; Neely JE; Landmeier B; Nelson D; Miraldi F
J Nucl Med; 1987 Oct; 28(10):1577-83. PubMed ID: 3655911
[TBL] [Abstract][Full Text] [Related]
5. Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
Borchardt PE; Yuan RR; Miederer M; McDevitt MR; Scheinberg DA
Cancer Res; 2003 Aug; 63(16):5084-90. PubMed ID: 12941838
[TBL] [Abstract][Full Text] [Related]
6. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes.
Kushner BH; Cheung NK
Cancer Res; 1991 Sep; 51(18):4865-70. PubMed ID: 1654202
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
8. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
[TBL] [Abstract][Full Text] [Related]
9. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma.
Heiner JP; Miraldi F; Kallick S; Makley J; Neely J; Smith-Mensah WH; Cheung NK
Cancer Res; 1987 Oct; 47(20):5377-81. PubMed ID: 3115567
[TBL] [Abstract][Full Text] [Related]
10. LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides.
Woodward J; Kennel SJ; Stuckey A; Osborne D; Wall J; Rondinone AJ; Standaert RF; Mirzadeh S
Bioconjug Chem; 2011 Apr; 22(4):766-76. PubMed ID: 21434681
[TBL] [Abstract][Full Text] [Related]
11. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
13. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody.
Wang CH; Huang YJ; Chang CW; Hsu WM; Peng CA
Nanotechnology; 2009 Aug; 20(31):315101. PubMed ID: 19597244
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
[TBL] [Abstract][Full Text] [Related]
16. Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats.
Bergman I; Pohl CR; Venkataramanan R; Burckart GJ; Stabin M; Barmada MA; Griffin JA; Cheung NK
J Immunother; 1999 Mar; 22(2):114-23. PubMed ID: 10093036
[TBL] [Abstract][Full Text] [Related]
17. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
19. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.
Cheung NK; Modak S; Lin Y; Guo H; Zanzonico P; Chung J; Zuo Y; Sanderson J; Wilbert S; Theodore LJ; Axworthy DB; Larson SM
J Nucl Med; 2004 May; 45(5):867-77. PubMed ID: 15136638
[TBL] [Abstract][Full Text] [Related]
20. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
